Join
Live feed
·
PRReleasevia Quantisnow
Principia Biopharma Inc. logo

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

ByQuantisnow·Wall Street's wire, on your screen.
PRNB· Principia Biopharma Inc.
Health Care
Full content unavailable. See the original source below.
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRNB (Principia Biopharma Inc.) and more on Quantisnow.